Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
According to Laplace s law loss of
2022-05-23

According to Laplace’s law, loss of myogenic response would increase wall stress and tension in downstream vessels and subsequently induce endothelial dysfunction and arterial stiffness [36]. Indeed, we found that arteries from FPR-1 KO mice presented with a leftward shift in the stress-strain curve
-
Corresponding to the different insulinotropic
2022-05-23

Corresponding to the different insulinotropic signaling, the competitive radioligand-binding studies demonstrated at least 3 distinct butein on GPR40: orthosteric binding site for endogenous ligands, allosteric binding site for partial agonists and another allosteric binding site for full agonists
-
It is considered that activations of MMP and MMP are
2022-05-23

It is considered that activations of MMP-2 and MMP-9 are closely related to progression process of cancer cells, such as invasion and metastasis [22], [23]. In fibrosarcoma cells, GPR40 suppressed not only MMP-2 and MMP-9 activations, but also cell motile and invasive activities, suggesting GPR40 ne
-
Although exhibited high inhibitory activity was found to be
2022-05-23

Although exhibited high inhibitory activity, was found to be metabolically unstable due to the hydrolysis of the phosphate group (data not shown), which prompted us to modify the phosphate moiety of . Comparison of the activities between three compounds bearing no or different spacer groups (, , a
-
To validate that our natural experiment operates primarily
2022-05-23

To validate that our natural experiment operates primarily through a large negative shock to the risk-taking incentives provided by option compensation measured by vega, we do two sets of tests. First, we confirm a significant drop in vega after the adoption of FAS 123R for treated firms relative to
-
Cholic acid In addition to Rabs several proteins
2022-05-23

In addition to Rabs, several proteins have been shown to interact with Rabphilin3a, for instance the GluN2A subunit of the NMDA receptor, PSD-95 ([56,57] and references therein), Rabaptin-5, α-actinin [16] and SNAP-25 [21,23,41,61]. Only the latter has been reported to participate in the AR. Explori
-
br Conclusion In conclusion our results demonstrate that inc
2022-05-23

Conclusion In conclusion, our results demonstrate that incubation of both LAD and SCA rat coronary arteries rapidly increases the ETB receptor-mediated contraction as well as upregulation of ETB receptor protein levels. These findings may have important experimental implications in tissue bath ex
-
Classical drugs target the viral enzymes reverse transcripta
2022-05-23

Classical drugs target the viral CEP-37440 reverse transcriptase (RT), protease and integrase (IN) [[4], [5], [6]]. Raltegravir (ISENTRESS/MK-0518) is the prototypical integrase strand transfer inhibitor (INSTI) leading to an extremely strong reduction in viral load [7] and it has been approved for
-
br Conclusion br Disclosure of interest br Introduction The
2022-05-23

Conclusion Disclosure of interest Introduction The Joint United Nations Program on HIV and AIDS (UNAIDS) proposed the ambitious global goal of achieving the "90-90-90" target by 2020 and ending the HIV epidemic by 2030 (Barton-Knott, 2014). One important measure is to monitor the incidence
-
In humans mutations in KDM A KDM B and KDM
2022-05-23

In humans, mutations in KDM5A, KDM5B, and KDM5C are found in patients with ID, implicating KDM5-regulated transcription in the development or activity of neuronal tissues (Vallianatos and Iwase, 2015). KDM5D is Y-linked, and its role in cognition remains uncharacterized. Mutations in KDM5C are the m
-
Fmoc-L-Arg(Aloc)2-OH Apoptosis is one of critical toxic mech
2022-05-23

Apoptosis is one of critical toxic mechanisms of benzene metabolites. In this work, overexpression of HIF-1a could significantly reduce the increase in cell apoptosis caused by 40 μM BQ. At the meanwhile, anti-apoptotic protein Bcl-2 level was significantly elevated in HIF-1a overexpression cells th
-
In tumor cells HK II induction is mediated by
2022-05-23

In tumor cells HK-II induction is mediated by Akt/mTOR pathway [6], [11]. HK-II dynamically shuttles between the mitochondria and cytoplasm under different metabolic conditions. In cardiomyocytes, Akt enhances HK-II binding to mitochondria, setting the heart at a state resistant to ischemic injury [
-
However despite medicinal chemistry efforts lead to consider
2022-05-23

However, despite medicinal chemistry efforts lead to considerable improvement in potency and selectivity of new HO-1 inhibitors, still have not identified inhibitors in the low nanomolar range. Therefore, due to the possible in vivo non-specific effects at high dosage, novel strategies should be dev
-
In our previous study we designed and synthesized
2022-05-23

In our previous study, we designed and synthesized compounds of A series from the starting material 4-hydroxy-3-methoxycinnamic BRD-9424 (ferulic acid). These compounds with R group being amino acid residues, fatty acyl group and sulfuryl group showed moderate HDAC inhibition and in vitro antitumor
-
br Methods br Results and
2022-05-23

Methods Results and discussion Conclusions In this work, 100-ns MDSs were applied on the WT and on the R155K and D168A single point mutations of the NS3/4A protease in the apo form and in complex with ASV, a current drug in phase III clinical trials. According to the PCA, these two mutation
15543 records 423/1037 page Previous Next First page 上5页 421422423424425 下5页 Last page